{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:07:41Z","timestamp":1789142861549,"version":"build-2803163510"},"reference-count":35,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"AbbVie","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To determine real-world dosing intervals for long-acting intravitreal anti\u2013vascular endothelial growth factor (anti-VEGF) therapies in patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Retrospective observational cohort study in American Academy of Ophthalmology IRIS\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Registry (Intelligent Research in Sight) patients with nAMD or DME treated with aflibercept 8 mg (aflibercept) or faricimab. Mean injection intervals during a \u226424-month period beginning 3 or 4 months after the initial injection were evaluated and descriptively contrasted with those in phase 3 clinical trials.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The mean dosing interval was 5\u20138, 9\u201312, and \u226513 weeks in 27.5%, 45.6%, and 25.8% of aflibercept-treated patients with nAMD (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 40,065); 27.0%, 43.4%, and 28.3% of aflibercept\u2013treated patients with DME (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 13,045); 40.5%, 36.1%, and 20.8% of faricimab-treated patients with nAMD (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 132,697); and 42.2%, 31.7%, and 22.5% of faricimab-treated patients with DME (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 39,849). Dosing intervals were consistent between treatment-na\u00efve and previously treated patients. In aflibercept phase 3 studies, 77% (nAMD) and 89% (DME) of patients achieved a 16-week dosing interval. In faricimab phase 3 studies, 45% (nAMD) and 52% (DME) of patients achieved a 16-week dosing interval.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Extension of injection intervals to 16 weeks is greatly reduced in real-world experience compared with phase 3 clinical studies. This discrepancy could be explained by protocol-mandated restrictive rescue criteria used in the registration studies, allowing injection only after vision loss and significant fluid recurrence. Current longer-acting anti-VEGF medications offer an extension to only 5\u201312 weeks for most patients in the real world.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10807683261484815","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:19:25Z","timestamp":1789028365000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Dosing Intervals for Long-Acting Anti-VEGF Intravitreal Injection Therapies in nAMD and DME: Academy IRIS\n                    <sup>\u00ae<\/sup>\n                    Registry Analysis"],"prefix":"10.1177","author":[{"given":"William R.","family":"Freeman","sequence":"first","affiliation":[{"name":"Jacobs Retina Center, University of California San Diego, La Jolla, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vail","sequence":"additional","affiliation":[{"name":"Jacobs Retina Center, University of California San Diego, La Jolla, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchen","family":"Ye","sequence":"additional","affiliation":[{"name":"AbbVie, Irvine, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"AbbVie, Irvine, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0004-6506","authenticated-orcid":false,"given":"Michael R.","family":"Robinson","sequence":"additional","affiliation":[{"name":"AbbVie, Irvine, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joice","family":"Huang","sequence":"additional","affiliation":[{"name":"AbbVie, Irvine, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle A.","family":"Hallak","sequence":"additional","affiliation":[{"name":"AbbVie, Irvine, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200926040-00002"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.6776"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.10.006"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2016.12.004"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2021-000957"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2022.04.003"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20230221-04"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.7085"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/24741264251332515"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00063-1"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00010-1"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)02577-1"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00018-6"},{"key":"e_1_3_3_19_1","unstructured":"18.American Academy of Ophthalmology. About the IRIS\u00ae Registry. 2026. Available from: https:\/\/www.aao.org\/iris-registry\/about [Last accessed: February1 2026]."},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/icu.0000000000000869"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100933"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2478755"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2025.129832"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-103539"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2025.08.022"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.02.014"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2025.10.028"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.12.026"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-023-06319-3"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-025-01252-6"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-025-03902-x"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-025-06931-5"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.farma.2025.12.002"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-025-00776-0"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.07.020"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/icu.0000000000001129"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261484815","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10807683261484815","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261484815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:16:16Z","timestamp":1789139776000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10807683261484815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":35,"alternative-id":["10.1177\/10807683261484815"],"URL":"https:\/\/doi.org\/10.1177\/10807683261484815","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"10807683261484815"}}